Stylus Medicine

Stylus Medicine is a private, pre-clinical biotech founded in 2021, based in Cambridge, MA. The company is developing a novel platform centered on engineered recombinases delivered via targeted LNPs to enable precise, in vivo gene insertion, aiming to create 'off-the-shelf' CAR-T therapies and other genetic medicines. Backed by prominent venture capital and led by an experienced team, Stylus is targeting a significant market opportunity in oncology, autoimmune, and genetic diseases by addressing key limitations of current cell and gene therapies.

Engineered recombinase platform for precise, targeted insertion of large therapeutic payloads into a genomic safe harbor, delivered via cell-targeted lipid nanoparticles (LNPs) for in vivo use.

Competes with other companies developing in vivo gene editing (e.g., using CRISPR) and non-viral delivery platforms, as well as next-generation ex vivo cell therapy companies. Differentiation hinges on demonstrating superior safety (no double-strand breaks) and payload capacity compared to nuclease-based approaches.